A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma

Oren Smaletz,Maria D P E Diz,Claudio C Do Carmo, Jorge Sabbaga,Geraldo F Cunhajunior,Sergio J Azevedo,Fernando C Maluf,Carlos H Barrios,Ronaldo L Costa, Ana G Fontana, Vivian Madrigal,Alberto J Wainstein,Fernanda P Yeda,Venâncio A Alves,Ana Maria Moro,Roberto Blasbalg,Andrew M Scott,Eric W Hoffman

Gynecologic Oncology（2015）

引用 21|浏览11

暂无评分

摘要

•Phase II study of hu3S193 in platinum resistant/refractory ovarian cancer patients.•Didn’t reach the primary endpoint whit mPFS of 8.4 weeks but safe toxicity profile.•mPFS was higher in patients with no ascites/no visceral disease.

查看译文

关键词

platinum resistant/refractory ovarian cancer,Anti Lewis-Y monoclonal antibody (hu3S193)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要